VANDA PHARMACEUTICALS INC. (VNDA) Operating Margin
- Operating margin · 12 months: Value -86.07%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -86.07% | Operating income / revenue. Period ending 2026-06-30. $-185.67M ÷ $215.72M × 100 ≈ -86.07% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -185.67M USD | Operating Income (Loss) |
| Revenue | 215.72M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 116.96M USD | Research and Development Expense |
| Selling, general and administration | 263.45M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-185.67M | $215.72M | (m) | $116.96M | $263.45M | -86.07% |
| 2026-03-31 | $-160.36M | $217.78M | (m) | $101.99M | $256.23M | -73.64% |
| 2025-12-31 | $-151.17M | $216.10M | (m) | $109.27M | $237.95M | -69.95% |
| 2025-09-30 | $-121.09M | $212.07M | (m) | $100.11M | $214.25M | -57.10% |
| 2025-06-30 | $-100.81M | $203.47M | (m) | $94.32M | $191.56M | -49.55% |
| 2025-03-31 | $-72.45M | $201.35M | (m) | $88.99M | $166.41M | -35.98% |
| 2024-12-31 | $-40.66M | $198.77M | (m) | $74.43M | $146.41M | -20.46% |
| 2024-09-30 | $-37.48M | $190.86M | (m) | $78.93M | $130.75M | -19.64% |
| 2024-06-30 | $-32.47M | $182.02M | (m) | $78.75M | $117.94M | -17.84% |
| 2024-03-31 | $-25.19M | $177.60M | (m) | $78.74M | $106.86M | -14.18% |
| 2023-12-31 | $-13.95M | $192.64M | (m) | $76.82M | $112.88M | -7.24% |
| 2023-09-30 | $-229.00K | $211.85M | (m) | $70.94M | $122.05M | -0.11% |
| 2023-06-30 | $9.67M | $238.35M | (m) | $79.19M | $127.14M | 4.06% |
| 2023-03-31 | $16.00M | $256.69M | (m) | $84.04M | $131.74M | 6.23% |
| 2022-12-31 | $6.33M | $254.38M | (m) | $85.77M | $136.49M | 2.49% |
| 2022-09-30 | $8.34M | $257.92M | (m) | $86.65M | $137.15M | 3.23% |
| 2022-06-30 | $15.25M | $262.70M | (m) | $81.44M | $139.75M | 5.80% |
| 2022-03-31 | $24.16M | $266.20M | (m) | $80.20M | $135.10M | 9.07% |
| 2021-12-31 | $42.16M | $268.68M | (m) | $75.36M | $124.05M | 15.69% |
| 2021-09-30 | $43.98M | $268.32M | (m) | $70.88M | $126.17M | 16.39% |
| 2021-06-30 | $40.90M | $258.53M | (m) | $63.53M | $127.72M | 15.82% |
| 2021-03-31 | $37.70M | $252.84M | (m) | $56.18M | $133.29M | 14.91% |
| 2020-12-31 | $27.24M | $248.17M | (m) | $55.58M | $140.51M | 10.98% |
| 2020-09-30 | $21.03M | $241.44M | (m) | $53.80M | $141.96M | 8.71% |
| 2020-06-30 | $24.05M | $240.62M | (m) | $52.85M | $138.18M | 9.99% |
| 2020-03-31 | $24.77M | $237.47M | (m) | $50.90M | $135.73M | 10.43% |
| 2019-12-31 | $22.81M | $227.19M | (m) | $48.65M | $129.74M | 10.04% |
| 2019-09-30 | $27.72M | $219.30M | (m) | $48.50M | $117.64M | 12.64% |
| 2019-06-30 | $23.19M | $208.95M | (m) | $48.54M | $113.47M | 11.10% |
| 2019-03-31 | $17.21M | $197.24M | (m) | $47.46M | $109.96M | 8.72% |
| 2018-12-31 | $21.74M | $193.12M | (m) | $43.59M | $105.75M | 11.26% |
| 2018-09-30 | $10.44M | $184.35M | (m) | $40.83M | $111.88M | 5.66% |
| 2018-06-30 | $-718.00K | $176.55M | (m) | $39.61M | $116.95M | -0.41% |
| 2018-03-31 | $-6.55M | $171.26M | (m) | $37.40M | $120.37M | -3.83% |
| 2017-12-31 | $-16.90M | $165.08M | (m) | $38.55M | $123.84M | -10.24% |
| 2017-09-30 | $-15.41M | $159.05M | (m) | $36.01M | $116.70M | -9.69% |
| 2017-06-30 | $-11.14M | $156.20M | (m) | $33.12M | $107.48M | -7.13% |
| 2017-03-31 | $-14.00M | $150.17M | (m) | $32.17M | $100.79M | -9.32% |
| 2016-12-31 | $-18.57M | $146.02M | (m) | $29.16M | $99.79M | -12.72% |
| 2016-09-30 | $-32.81M | $139.62M | (m) | $30.29M | $104.76M | -23.50% |
| 2016-06-30 | $-41.70M | $129.48M | (m) | $32.97M | $101.31M | -32.20% |
| 2016-03-31 | $-42.37M | $121.04M | (m) | $32.22M | $95.02M | -35.00% |
| 2015-12-31 | $-40.19M | $109.92M | (m) | $29.14M | $84.53M | -36.56% |
| 2015-09-30 | $44.40M | $93.44M | (m) | $25.15M | $72.97M | 47.52% |
| 2015-06-30 | $52.49M | $79.88M | (m) | $18.88M | $65.80M | 65.71% |
| 2015-03-31 | $36.35M | $63.16M | (m) | $16.45M | $75.56M | 57.54% |
| 2014-12-31 | $20.06M | $50.16M | (m) | $19.23M | $84.64M | 40.00% |
| 2014-09-30 | $-56.62M | $43.57M | (m) | $20.44M | (m) | -129.95% |
| 2014-06-30 | $-60.61M | $37.50M | (m) | $24.76M | (m) | -161.63% |
| 2014-03-31 | $-42.41M | $34.95M | (m) | $27.34M | (m) | -121.34% |
| 2013-12-31 | $-20.40M | $33.88M | (m) | $28.19M | (m) | -60.21% |
| 2013-09-30 | $-19.16M | $33.02M | (m) | $32.59M | (m) | -58.04% |
| 2013-06-30 | $-19.15M | $32.59M | (m) | $34.72M | (m) | -58.75% |
| 2013-03-31 | $-24.13M | $32.65M | (m) | $41.23M | (m) | -73.89% |
| 2012-12-31 | $-28.23M | $32.73M | (m) | $45.45M | (m) | -86.24% |
| 2012-09-30 | $-27.70M | $33.18M | (m) | $45.38M | (m) | -83.51% |
| 2012-06-30 | $-25.60M | $32.86M | (m) | $43.40M | (m) | -77.92% |
| 2012-03-31 | $-19.03M | $31.91M | (m) | $36.91M | (m) | -59.64% |
| 2011-12-31 | $-10.71M | $31.27M | (m) | $29.00M | (m) | -34.24% |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $8.84M | $35.71M | (m) | $12.34M | (m) | 24.75% |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $-35.95M | $4.55M | (m) | $13.87M | (m) | -790.41% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |